Fennec Pharmaceuticals Inc. (NASDAQ:FENC) will release earnings results for its fourth quarter, before the opening bell on Tuesday, March 24.
Analysts expect the Research Triangle Park, North Carolina-based company to report quarterly earnings at 4 cents per share, versus a year-ago loss of 6 cents per share. The consensus estimate for Core & Main's quarterly revenue is $14.73 million, versus $7.92 million a year earlier, according to data from Benzinga Pro.
On March 16, Fennec Pharmaceuticals announced a settlement agreement resolving PEDMARK patent litigation.
Fennec Pharmaceuticals shares gained 1.8% to close at $7.45 on Monday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.
- Piper Sandler analyst David Amsellem initiated coverage on the stock with an Overweight rating and a price target of $18 on Jan. 9, 2026. This analyst has an accuracy rate of 75%.
- HC Wainwright & Co. analyst Raghuram Selvaraju maintained a Neutral rating with a price target of $13 on Aug. 21, 2025. This analyst has an accuracy rate of 66%.
- Craig-Hallum analyst Chase Knickerbocker maintained a Buy rating and boosted the price target from $13 to $14 on Aug. 15, 2025. This analyst has an accuracy rate of 77%.
Considering buying FENC stock? Here’s what analysts think:
Photo via Shutterstock
